Potential Eligibility for Lecanemab in a Cohort of Alzheimer’s Dementia Patients from India
A substantial proportion (80.75%) of dementia patients from LMICs may be ineligible for lecanemab due to diagnostic and resource limitations. However, 20.8% of clinically diagnosed AD could potentially be eligible with biomarker testing. Efforts to enhance biomarker availability, early detection, and cost-effective strategies are crucial to enable equitable access to emerging AD therapies in LMICs.
Authors
- Suvarna Alladi (ORCID: https://orcid.org/0000-0002-0372-9572)
- Sivasubramanian Ramakrishnan (ORCID: https://orcid.org/0000-0001-5489-0748)
- P Sastry
- Mahammad Samim Mondal (ORCID: https://orcid.org/0000-0002-3367-1455)
- Sarath Govindaraj
- S Sandeep Kumar
- Faheem Arshad
Institutions
- National Institute of Mental Health and Neurosciences (IN)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_106469
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00